Regional differences in the extracellular matrix of the human spongy urethra as evidenced by the composition of glycosaminoglycans

PURPOSE: Despite the concept that the spongy urethra is a unique entity clinical evidence suggests the existence of segmental structural differences. The spongy urethra has a vascular nature, its cells may express different phenotypes and the extracellular matrix that they synthesize should reflect these differences. Glycosaminoglycans are components of the extracellular matrix that have key roles in the normal physiology and pathology of several tissues. Although total collagen content of the urethra was determined, we also analyzed urethral glycosaminoglycans (GAGs). MATERIALS AND METHODS: Fresh, macroscopically normal cadaveric urethral samples were obtained from 15 men who died at a mean age of 25.4 years. The urethra was divided into glanular, penile and bulbar segments, which were then analyzed separately. Total GAG concentration was assessed by hexuronic acid assay and expressed as microg. hexuronic acid per mg. dry tissue, while the proportions of sulfated GAGs were determined by agarose gel electrophoresis. Hyaluronan concentration was determined by ion exchange chromatography and total tissue collagen was estimated as hydroxyproline content. RESULTS: Total GAG concentration was heterogeneous along the spongy urethra (p <0.001). Mean values plus or minus standard deviation in the glanular, penile and bulbar segments were 2.53 +/- 0.42, 2.11 +/- 0.47 and 1.47 +/- 0.4 microg./mg., respectively. The most predominant GAG was hyaluronan and its highest mean concentration of 50.1% +/- 3.7% was found in the glanular urethra. The most predominant sulfated GAG in the male urethra was dermatan sulfate, followed by chondroitin sulfate and heparan sulfate. Total collagen content and the GAG-to-collagen ratio varied along the spongy urethra and were lowest in the bulbar segment. CONCLUSIONS: The extracellular matrix of the human spongy urethra shows regional differences, as evidenced by biochemical analysis of GAG and collagen. This heterogeneity implies functional adaptations in the various segments and may affect the physiology and segmental incidence of urethral diseases.     

Facial clefts involving the midline in combination with intracranial anomalies: Case studies illustrating surgical treatment and medical substitution

Abstract Malm? and Uppsala have been regional centres for the treatment of cleft lip and palate since the beginning of the 1950s. We have about 80 new cases every year and most patients have conventional oronasal clefts, either cleft lip and palate or isolated cleft palate. During a 10-year period we have come across four patients who have had varying degrees of midface dysplasia combined with intracranial anomalies. One child died at an early age, but the other three children were given medical substitution of hypopituitarism and have had their clefts reconstructed.     

Large inter-rater variability on EEG-reactivity is improved by a novel quantitative method

Objective

To assess inter-rater agreement on EEG-reactivity (EEG-R) in comatose patients and compare it with a quantitative method (QEEG-R).

Anti-Candida,docking studies,and in vitro metabolism-mediated cytotoxicity evaluation of Eugenol derivatives

The high morbidity and mortality rates of Candida infections, especially among immunocompromised patients, are related to the increased resistance rate of these species and the limited therapeutic arsenal. In this context, we evaluated the anti-Candida potential and the cytotoxic profile of eugenol derivatives. Anti-Candida activity was evaluated on C. albicans and C. parapsilosis strains by minimum inhibitory concentration (MIC), scanning electron microscopy (SEM), and molecular docking calculations at the site of the enzyme lanosterol-14-α-demethylase active site, responsible for ergosterol formation. The cytotoxic profile was evaluated in HepG2 cells, in the presence and absence of the metabolizing system (S9 system). The results indicated compounds 1b and 1d as the most active ones. The compounds have anti-Candida activity against both strains with MIC ranging from 50 to 100 μg ml⁻¹. SEM analyses of 1b and 1d indicated changes in the envelope architecture of both C. albicans and C. parapsilosis like the ones of eugenol and fluconazole, respectively. Docking results of the evaluated compounds indicated a similar binding pattern of fluconazole and posaconazole at the lanosterol-14-α-demethylase binding site. In the presence of the S9 system, compound 1b showed the same cytotoxicity profile as fluconazole (1.08 times) and compound 1d had 1.23 times increase in cytotoxicity. Eugenol and other evaluated compounds showed a significant increase in cytotoxicity. Our results suggest compound 1b as a promising starting point candidate to be used in the design of new anti-Candida agent prototypes.     

A 1-year pilot study of intralymphatic injections of GAD-alum in individuals with latent autoimmune diabetes in adults (LADA) with signs of high immunity: No safety concerns and resemblance to juvenile type 1 diabetes

Aims

To test, for the first time in latent autoimmune diabetes in adults (LADA), the effects of autoantigen-specific immunotherapy by intralymphatic administration of aluminium-formulated recombinant human glutamic acid decarboxylase 65 (GAD-alum); specifically, to test if this treatment is safe, to test whether it induces a strong immunological response akin to a similar protocol in type 1 diabetes and to look for associations with preserved beta-cell function.

Materials and Methods

Three GAD-alum injections, 4 μg each, were administered 1 month apart into an inguinal lymph node in 14 people with newly diagnosed LADA (age 30-62 years) presenting with high levels of antibodies against glutamic acid decarboxylase (GADA). Adverse effects, immunological variables and beta-cell function were monitored, with detailed measurements at 5 and 12 months from baseline.

Results

Clinical adverse effects were minor and transient and measured laboratory variables were unaffected. All participants completed the study. Treatment raised levels of GADA, elicited strong effects on reactivity of peripheral blood mononuclear cells to GAD and raised cytokine/chemokine levels. Beta-cell function appeared stable preferentially in the seven participants carrying human leukocyte antigen (HLA) haplotypes DR3DQ2, as assessed by C-peptide glucagon tests (P < 0.05 vs. seven non-carriers).

Conclusion

Intralymphatic treatment with GAD-alum in LADA is without clinical or other safety concerns over a 12-month period. As in a similar protocol used in type 1 diabetes, treatment exerts a strong immunological impact and is compatible with protection of beta-cell function preferentially in HLA-DR3DQ2 LADA patients. These findings pave the way for a randomized controlled trial in this important subgroup of LADA patients.